We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vertex’s CF Combo Treatment Shows Some Potential
Vertex’s CF Combo Treatment Shows Some Potential
June 22, 2011
Interim results from a Phase II study show the combination of Vertex Pharmaceuticals’ VX-770 and VX-809 met primary endpoints in treating the defective protein that causes cystic fibrosis (CF) but still may be disappointing in the short-term, an analyst says.